News & Updates
Filter by Specialty:
Belimumab after rituximab reduces risk for severe flare in SLE
Treatment with belimumab following rituximab significantly lowers serum IgG anti-dsDNA antibody levels and the risk for severe flare in patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, reveals a study.
Belimumab after rituximab reduces risk for severe flare in SLE
10 Nov 2021
A3 adenosine receptor agonist safe, effective for treating NAFLD
Namodenoson, an A3 adenosine receptor (A3AR) agonist, shows clinical activity against nonalcoholic fatty liver disease (NAFLD) with or without nonalcoholic steatohepatitis (NASH), according to data from a phase II study.
A3 adenosine receptor agonist safe, effective for treating NAFLD
10 Nov 2021
Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics
Type 2 diabetes (T2D) patients exposed to hydrochlorothiazide for more than 2 years appear to be at higher risk of cutaneous squamous cell carcinoma (cSCC), as reported in a recent study.
Hydrochlorothiazide use poses risk of cutaneous squamous cell carcinoma among diabetics
09 Nov 2021
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
Fatty acid synthase (FASN) is commonly expressed in operable triple-negative breast cancer (TNBC) and is associated with a poor prognosis, but omeprazole can hamper FASN activity, which may potentially boost the efficacy of neoadjuvant chemotherapy, according to the results of a phase II study.
Omeprazole helps inhibit fatty acid synthase activity in triple-negative breast cancer
08 Nov 2021
Quadruple therapy with empagliflozin/dapagliflozin affords long-term glycaemic control
A four-drug combination that includes either empagliflozin or dapagliflozin helps keep glucose in check through 3 years for patients with type 2 diabetes (T2D), in addition to its positive effect on weight and tolerable safety profile, as shown in an open-label randomized controlled study.